Anna-Karin Wikström1, Lina Ekegren1, Mathias Karlsson2, Johan Wikström3, Mikael Bergenheim4, Helena Ǻkerud5. 1. Department of Women's and Children's Health, Uppsala University, SE-751 85 Uppsala, Sweden. 2. Department of Clinical Science and Education, Karolinska Institute at Stockholm Söder Hospital, Sweden; Department of Clinical Research, Karlstad, Sweden. 3. Department of Oncology, Radiology and Radiation Science, Uppsala University, Uppsala, Sweden. 4. Department of Surgery, Central Hospital Karlstad, Karlstad, Sweden. 5. Department of Women's and Children's Health, Uppsala University, SE-751 85 Uppsala, Sweden. Electronic address: helena.akerud@kbh.uu.se.
Abstract
OBJECTIVE: S100B is suggested to be a peripheral biomarker of central nervous system injury with increased blood-brain barrier permeability. The aim of this study was to investigate if there is a difference in plasma levels of S100B throughout pregnancy between women developing pre-eclampsia and those who did not. STUDY DESIGN: A nested case-control study within a longitudinal study cohort was performed. Healthy pregnant women were enrolled and plasma samples were collected at gestational weeks 10, 25, 28, 33 and 37. Levels of S100B throughout pregnancy were analyzed with an ELISA assay. RESULTS: The levels of S100B did not change between gestational weeks 10 and 37 (0.047 vs. 0.052; p=0.71) in the healthy controls, but the S100B levels increased between corresponding weeks in women who developed pre-eclampsia (0.052 vs. 0.075; p<0.05). In gestational weeks 33 and 37 women who developed pre-eclampsia had higher levels of S100B than the controls (p=0.047 and p=0.010, respectively). CONCLUSION: S100B levels increase during pregnancy in women who develop pre-eclampsia and there is an increased S100B level in women who develop pre-eclampsia compared with healthy pregnancies several weeks before clinical symptoms of the disease. The increased amount of plasma S100B in women developing pre-eclampsia might be secondary to cerebral vascular damage and S100B is a potential peripheral biomarker reflecting cerebral involvement in pre-eclampsia.
OBJECTIVE:S100B is suggested to be a peripheral biomarker of central nervous system injury with increased blood-brain barrier permeability. The aim of this study was to investigate if there is a difference in plasma levels of S100B throughout pregnancy between women developing pre-eclampsia and those who did not. STUDY DESIGN: A nested case-control study within a longitudinal study cohort was performed. Healthy pregnant women were enrolled and plasma samples were collected at gestational weeks 10, 25, 28, 33 and 37. Levels of S100B throughout pregnancy were analyzed with an ELISA assay. RESULTS: The levels of S100B did not change between gestational weeks 10 and 37 (0.047 vs. 0.052; p=0.71) in the healthy controls, but the S100B levels increased between corresponding weeks in women who developed pre-eclampsia (0.052 vs. 0.075; p<0.05). In gestational weeks 33 and 37 women who developed pre-eclampsia had higher levels of S100B than the controls (p=0.047 and p=0.010, respectively). CONCLUSION:S100B levels increase during pregnancy in women who develop pre-eclampsia and there is an increased S100B level in women who develop pre-eclampsia compared with healthy pregnancies several weeks before clinical symptoms of the disease. The increased amount of plasma S100B in women developing pre-eclampsia might be secondary to cerebral vascular damage and S100B is a potential peripheral biomarker reflecting cerebral involvement in pre-eclampsia.
Authors: S Elbagir; N A Mohammed; H Kaihola; E Svenungsson; I Gunnarsson; V A Manivel; E Pertsinidou; E M Elagib; M A M Nur; E A Elussein; A Elshafie; H Åkerud; J Rönnelid Journal: Lupus Date: 2020-02-27 Impact factor: 2.911
Authors: Malin Andersson; Jonatan Oras; Sven Egron Thörn; Ove Karlsson; Peter Kälebo; Henrik Zetterberg; Kaj Blennow; Lina Bergman Journal: PLoS One Date: 2021-02-08 Impact factor: 3.240
Authors: Lina Bergman; Henrik Zetterberg; Helena Kaihola; Henrik Hagberg; Kaj Blennow; Helena Åkerud Journal: PLoS One Date: 2018-05-02 Impact factor: 3.240